证券代码：688253 证券简称：英诺特 公告编号：2025-002 北京英诺特生物技术股份有限公司 2024 年年度业绩预告的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2024 年 1 月 1 日至 2024 年 12 月 31 日。 （二）业绩预告情况 经财务部门初步测算，预计北京英诺特生物技术股份有限公司（以下简称"公 司"）2024年年度可实现营业收入约为人民币62,133.85万元，同比增长约29.98%。 预计公司2024年年度归属于上市公司股东的净利润约为人民币24,570.01万 元，同比增长约 41.25%。 （三）审计情况 本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况 以上预告数据仅为初步核算数据，具体准确的财务数据以公司正式披露的 2024 年年度报告为准，敬请广大投资者注意投资风险。 特此公告。 北京英诺特生物技术股份有限公司董事会 2025 年 1 月 24 日 2 / 2 2023 年度，公司实现营业收入 47 ...

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-014 | --- | --- | --- | --- | |-----------------------------------------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | 投资者关系活 动类别 | £ □ | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 ...

呼吸道系列产品增长迅速，海外市场可期 证 券 研 究 报 告 ——英诺特 2024 年三季报业绩点评 公 司 研 究 公 司 点 评 ◼ 事件描述 公司发布 2024 年三季度报告, 业绩快速增长：2024 年前三季度收入 约 5.21 亿元，同比增长 87.05%；归母净利润约 2.45 亿元，同比增长 182.65%；扣非归母净利润约 2.24 亿元，同比增长 239.12%。前三季 度公司毛利率、归母净利率、扣非归母净利率分别为 81.0%、47.0%、 43.0%，分别提升 9.35 个百分点、15.88 个百分点、19.27 个百分点。 24Q3 毛利率、归母净利率、扣非归母净利率分别为 78.2%、38.4%、 32.5%，同比提升 3.69 个百分点、21.8 个百分点、26.41 个百分点。 ◼ 核心观点 呼吸道系列非新冠产品增长迅速：公司业务主要由呼吸道系列-非新冠 产品构成，据财报显示，2023 年该业务收入占比约 84.83%，到 2024 年上半年，该占比更是高达 97.74%；公司产品主要包括全血呼吸五项 检测试剂盒、流感抗原三项检测试剂盒、流感抗体三项检测试剂盒， 等等。2024 ...

证券代码：688253 证券简称：英诺特 北京英诺特生物技术股份有限公司 投资者关系活动记录表 编号：2024-013 | --- | --- | |---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活 动类别 | 特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 ☑路演活动 现场参观 □其他（券商策略会） | | 参与单位名称 及人员姓名 | 三头牛基金：林伟杰；嘉强私募：王子帅；银国达资本：梁志安；明勤基 金：朱一平； ...

证券代码：688253 证券简称：英诺特 公告编号：2024-056 北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/3 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 万股 118.6052 | | 累计已回购股数占总股本比例 | 0.8692% | | 累计已回购金额 | 5,001.26 万元 | | 实际回购价格区间 | 35.93 元/股~45.37 元/股 | 一、 回购股份的基本情况 2024 年 8 月 2 日，公司召开第二届董事会第五次会议，会议审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-055 北京英诺特生物技术股份有限公司关于认购私募基 金份额暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1 / 2 市公司重大资产重组管理办法》规定的重大资产重组。减资完成后，泓创海河出 资额合计为 20,613.00 万元，景达广源认缴出资 1,250.00 万元，认缴出资占基金 总认缴出资额的比例降低至 6.06%。 三、其他事项 一、对外投资暨关联交易概述 北京英诺特生物技术股份有限公司（以下简称"公司"）于 2023 年 11 月 30 日召开第二届董事会第二次会议、第二届监事会第二次会议，同意公司之全资子 公司北京景达广源科技发展有限公司（以下简称"景达广源"）作为天津泓创海 河创业投资合伙企业（有限合伙）（以下简称"泓创海河"）之有限合伙人，以自 有资金认缴出资人民币 2,000.00 万元，出资比例占基金总认缴出资额的 11.80%。 具 体 内 容 详 见 公 司 于 2023 年 12 月 2 日 在 上 海 证 券 ...

[Table_MainInfo] 公司研究/医药与健康护理/医疗保健设备与用品 证券研究报告 英诺特（688253）公司季报点评 2024 年 11 月 13 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-------------------------------------------------------------|-------------| | 股票数据 | | | 11 [ Table_StockInfo 月 12 日收盘价（元） ] | 44.13 | | 52 周股价波动（元） | 23.45-52.69 | | 总股本 / 流通 A 股（百万股） | 136/69 | | 总市值 / 流通市值（百万元） | 6022/3037 | | 相关研究 | | | [Table_ReportInfo] 《国内感染快检龙头，小而美却大有可为》 | | | 2024.03.17 | | 市场表现 [Table_QuoteInfo] -25.64% 0.36% 26.36% 52.36% 78.36% 2023/11 2024/2 2024/5 2 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights steady improvement in market penetration and anticipates significant growth in both domestic and overseas markets in the fourth quarter [1] - The company reported a total revenue of 521 million yuan for the third quarter, representing an increase of 87.05%, with a net profit attributable to the parent company of 245 million yuan, up 182.65% [1] - The report emphasizes that the profit growth rate significantly outpaces revenue growth, with a notable increase in core revenue driven by the rise in respiratory multi-detection products [1] Summary by Sections Financial Performance - For the third quarter, the company achieved a revenue of 521 million yuan, with a net profit of 245 million yuan, and a non-recurring net profit of 224 million yuan, reflecting increases of 87.05%, 182.65%, and 239.12% respectively [1] - The company’s core revenue showed a rapid growth trend, with a year-on-year increase of 250% [5] Future Outlook - The third quarter is viewed as a turning point for annual revenue, with expectations for rapid growth in the fourth quarter driven by increased demand for respiratory multi-detection products [1] - The company has received approvals for two multi-detection products in Malaysia and Myanmar, which cover 15 types of respiratory pathogens, indicating strong potential for market expansion [1] Financial Projections - The company is projected to achieve revenue growth rates of 67.8%, 41.7%, and 34.6% for the years 2024, 2025, and 2026 respectively, with net profits expected to reach 396 million yuan, 569 million yuan, and 758 million yuan in the same years [5][6] - The report forecasts an increase in gross margin from 76.0% in 2023 to 88.3% in 2024, indicating improved profitability [5]

北京英诺特生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688253 证券简称：英诺特 公告编号：2024-054 截至 2024 年 10 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式回购公司股份 350,385 股，占公司总股本 136,458,196 股的比例为 0.2568%， 回购成交的最高价为 42.00 元/股，最低价为 35.93 元/股，支付的资金总额为人民 币 14,438,551.17 元（不含印花税、交易佣金等交易费用）。 三、 其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 北京英诺特生物技术股份有限公司董事会 2024 年 11 月 4 日 | 回购方案首次披露日 | ...

Financial Performance - Total operating income for the first three quarters of 2024 reached 520,820,403.02 RMB, a significant increase from 278,434,984.25 RMB in the same period of 2023[17] - Net profit for the first three quarters of 2024 was 244,605,662.28 RMB, a substantial rise from 86,539,519.51 RMB in the same period of 2023[19] - Comprehensive income for the first three quarters of 2024 reached 241,113,891.70 RMB, an increase of 87,844,399.88 RMB compared to the same period last year[20] - Basic and diluted earnings per share for the first three quarters of 2024 were both 1.80 RMB, up from 0.64 RMB in the same period last year[20] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were 247,200,900.72 RMB, compared to 172,676,941.47 RMB in the same period of 2023[18] - R&D expenses increased to 60,987,843.21 RMB in the first three quarters of 2024, up from 34,402,685.84 RMB in the same period of 2023[18] - Sales expenses rose to 55,547,509.40 RMB in the first three quarters of 2024, compared to 32,632,554.07 RMB in the same period of 2023[18] Liabilities and Equity - Contract liabilities increased to 100,655,839.49 RMB in 2024, up from 32,461,122.42 RMB in the previous year[15] - Total liabilities for 2024 were 223,646,680.00 RMB, compared to 126,424,020.97 RMB in the previous year[16] - Total equity attributable to the parent company's shareholders increased to 2,043,709,845.59 RMB in 2024, up from 1,842,008,497.63 RMB in the previous year[16] - Total assets and liabilities combined reached 2,065,655,177.63 RMB in 2024, up from 2,170,133,866.56 RMB in the previous year[16] Cash Flow - Cash received from sales of goods and services in the first three quarters of 2024 was 509,770,329.71 RMB, a significant increase from 219,325,256.10 RMB in the same period last year[20] - Cash flow from operating activities for the first three quarters of 2024 was 214,181,071.15 RMB, compared to 41,519,953.07 RMB in the same period last year[21] - Cash flow from investing activities for the first three quarters of 2024 was 216,791,661.90 RMB, a significant improvement from -221,164,887.41 RMB in the same period last year[21] - Cash and cash equivalents at the end of the third quarter of 2024 were 543,759,840.18 RMB, compared to 155,972,119.66 RMB at the end of the same period last year[22] - The company received 3,499,300,811.67 RMB from investment recoveries in the first three quarters of 2024, up from 2,536,782,393.51 RMB in the same period last year[21] - The company paid 54,424,326.40 RMB in dividends, profits, or interest payments in the first three quarters of 2024, compared to 24,394,958.16 RMB in the same period last year[22] - The company's cash outflow for purchasing goods and accepting services in the first three quarters of 2024 was 92,135,917.78 RMB, up from 74,993,688.59 RMB in the same period last year[20] - The company's cash outflow for employee compensation and benefits in the first three quarters of 2024 was 72,165,183.38 RMB, compared to 56,038,966.51 RMB in the same period last year[21] Other Comprehensive Income - Other comprehensive income after tax for the first three quarters of 2024 was -3,491,770.58 RMB, compared to 1,304,880.37 RMB in the same period of 2023[19]